ZAZZI MAURIZIO | Elenco docenti

Clemente, T., Torkjazi, G., Capra, N., Gagliardini, R., Cattelan, A.M., Lolatto, R., et al. (2026). Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(1) [10.1093/jac/dkaf415]. - dettaglio
Giammarino, F., Paletti, C., Bartolini, N., Fiaschi, L., Biba, C., Varasi, I., et al. (2025). Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro. ANTIVIRAL RESEARCH, 239 [10.1016/j.antiviral.2025.106157]. - dettaglio
Rossi, S., Deidda, G., Fiaschi, L., Ibba, R., Pieroni, M., Dichiara, M., et al. (2025). Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3. ARCHIV DER PHARMAZIE, 358(1) [10.1002/ardp.202400812]. - dettaglio
Amodeo, D., Marchi, S., Fiaschi, L., Raucci, L., Biba, C., Salvestroni, V., et al. (2025). Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm). APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 91(6) [10.1128/aem.00403-25]. - dettaglio
Martina, M.G., Vagaggini, C., Dreassi, E., De Angelis, M., Nencioni, L., Dragoni, F., et al. (2025). Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration. SCIENTIFIC REPORTS, 15(1) [10.1038/s41598-025-14001-3]. - dettaglio